Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mircera maintenance in chronic renal anemia
NCT00517413Phase 3Completed
- Sponsor
- Roche
- Start
- Oct 2007
- Primary completion
- May 2010
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 9
01
Overview
Phase 3, open-label, single-arm trial of methoxy polyethylene glycol-epoetin beta in anemia of chronic kidney disease (CKD-A), sponsored by Roche. Primary endpoint: Percentage of Participants Maintaining Their Mean Hb Concentration Within ±1.0 Gram/Deciliter of Their Reference Hb and Between 10.5 and 12.5 Gram/Deciliter. Started Oct 2007; status: completed.
02
Drugs
methoxy polyethylene glycol-epoetin beta
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT00517413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00517413.